SAN FRANCISCO—Michael Chi, the Chief Commercial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of stock transactions involving the company's Class A common stock. According to a filing with the Securities and Exchange Commission, Chi sold 7,259 shares on January 10, 2025, at a per-share price of $24.07, totaling approximately $174,724.
In addition to the sale, Chi exercised stock options to acquire 7,259 shares at a price of $6.82 per share, amounting to a total transaction value of $49,506. These transactions were conducted under a Rule 10b5-1 trading plan, which Chi adopted on March 1, 2024.
Following these transactions, Chi holds 193,601 shares of Hims & Hers Health, maintaining a direct ownership stake in the company.
In other recent news, Hims & Hers Health has garnered significant attention from financial analysts. BTIG initiated coverage on the company with a Buy rating, citing robust revenue growth and high demand for its health services. Similarly, Needham & Company named Hims & Hers their top pick for 2025, highlighting the company's diverse growth strategies. Morgan Stanley (NYSE:MS) also initiated coverage on the company, assigning it an Overweight rating due to its significant growth potential.
On the earnings front, Hims & Hers reported a 77% year-over-year increase in Q3 sales, surpassing $400 million, and an adjusted EBITDA over $50 million. The company's Q4 2024 revenue projections range between $465 million and $470 million, indicating a significant year-over-year increase.
In terms of partnerships, Hims & Hers announced a collaboration with Eli Lilly (NYSE:LLY) to streamline access to FDA-approved obesity medication Zepbound. However, the FDA's recent resolution of the tirzepatide injection shortage could alter market dynamics for obesity drugs, impacting companies like Hims & Hers that have been offering compounded versions of such medications.
In other developments, digital health company Ro also announced a partnership with Eli Lilly to facilitate access to Zepbound. These recent developments underscore Hims & Hers' active role in the digital health sector and its commitment to growth and innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.